Interleukin-6, a Major Cytokine in the Central Nervous System

被引:831
作者
Erta, Maria [2 ]
Quintana, Albert [3 ,4 ]
Hidalgo, Juan [1 ,2 ]
机构
[1] Univ Autonoma Barcelona, Fac Biociencias, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, E-08193 Barcelona, Spain
[2] Univ Autonoma Barcelona, Fac Biociencias, Inst Neurociencias, E-08193 Barcelona, Spain
[3] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA
[4] Univ Washington, Dept Biochem, Seattle, WA 98195 USA
来源
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2012年 / 8卷 / 09期
关键词
Neuropoietin; Neuroinflammation; Neurogenesis; Gliogenesis; Alzheimer's disease; Multiple Sclerosis; Stroke; Trauma; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TUMOR-NECROSIS-FACTOR; HUMAN ASTROCYTOMA-CELLS; SOLUBLE IL-6 RECEPTOR; ACTIVATED PROTEIN-KINASE; STIMULATORY FACTOR-II; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; POSTTRAUMATIC-STRESS-DISORDER; VASOACTIVE-INTESTINAL-PEPTIDE; SPORADIC ALZHEIMERS-DISEASE;
D O I
10.7150/ijbs.4679
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Interleukin-6 (IL-6) is a cytokine originally identified almost 30 years ago as a B-cell differentiation factor, capable of inducing the maturation of B cells into antibody-producing cells. As with many other cytokines, it was soon realized that IL-6 was not a factor only involved in the immune response, but with many critical roles in major physiological systems including the nervous system. IL-6 is now known to participate in neurogenesis (influencing both neurons and glial cells), and in the response of mature neurons and glial cells in normal conditions and following a wide arrange of injury models. In many respects, IL-6 behaves in a neurotrophin-like fashion, and seemingly makes understandable why the cytokine family that it belongs to is known as neuropoietins. Its expression is affected in several of the main brain diseases, and animal models strongly suggest that IL-6 could have a role in the observed neuropathology and that therefore it is a clear target of strategic therapies.
引用
收藏
页码:1254 / 1266
页数:13
相关论文
共 251 条
[101]   Anti-interleukin-6 therapy for Crohn's disease [J].
Ito, H .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (04) :295-305
[102]  
JIRIK FR, 1989, J IMMUNOL, V142, P144
[103]   Directing transition from innate to acquired immunity defining a role for IL-6 [J].
Jones, SA .
JOURNAL OF IMMUNOLOGY, 2005, 175 (06) :3463-3468
[104]   The soluble interleukin 6 receptor: mechanisms of production and implications in disease [J].
Jones, SA ;
Horiuchi, S ;
Topley, N ;
Yamamoto, N ;
Fuller, GM .
FASEB JOURNAL, 2001, 15 (01) :43-58
[105]   Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling [J].
Jones, Simon A. ;
Scheller, Juergen ;
Rose-John, Stefan .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (09) :3375-3383
[106]   Neuroprotection by Interleukin-6 Is Mediated by Signal Transducer and Activator of Transcription 3 and Antioxidative Signaling in Ischemic Stroke [J].
Jung, Joo Eun ;
Kim, Gab Seok ;
Chan, Pak H. .
STROKE, 2011, 42 (12) :3574-U371
[107]   Intranasal administration of human IL-6 increases the severity of chemically induced seizures in rats [J].
Kalueff, AV ;
Lehtimaki, KA ;
Ylinen, A ;
Honkaniemi, J ;
Peltola, J .
NEUROSCIENCE LETTERS, 2004, 365 (02) :106-110
[108]   INTERLEUKIN-6 FAMILY OF CYTOKINES AND GP130 [J].
KISHIMOTO, T ;
AKIRA, S ;
NARAZAKI, M ;
TAGA, T .
BLOOD, 1995, 86 (04) :1243-1254
[109]  
Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO
[110]  
2-W